221 CRESCENT ST., WALTHAM, MA
News, Underwriting Agreement, Securities Holder Rights or Indentures, Legal Opinion
Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
Shareholder votes
Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
Annual Report to Security Holders
Material Contracts
Provides Pipeline Progress and Reports Full Year 2024 Financial Results
Q2
FY 2024
Q3
Q1
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
S-1MEF
Correspondence